We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Cancer-Associated Mutations Found in Patients with Unexplained Cytopenias

By LabMedica International staff writers
Posted on 17 Nov 2015
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS).

Myelodysplastic syndromes (MDS) are clonal bone mar row disorders characterized by inefficient and dysmorphic hematopoietic differentiation, cytopenias of the peripheral blood, and increased risk of transformation to acute myeloid leukemia (AML). More...


Scientists at the Moores Cancer Center, (La Jolla, CA, USA) and their colleagues performed a prospective study to examine the frequency and types of mutations encountered in 144 patients with unexplained cytopenias. Patients had a complete medical history as well as screening tests that included a complete blood count with differential, iron studies, reticulocyte count, erythropoietin level, vitamin B12, and folate levels.

Genomic DNA was extracted from the bone marrow aspirate samples and selected exons and flanking sequences of 22 myeloid genes were amplified by multiplex polymerase chain reaction (PCR). Libraries were created using a Fluidigm Access Array system (Fluidigm Corporation; South San Francisco, CA, USA). Amplicon libraries were split to be sequenced on the Illumina MiSeq platform (Illumina; San Diego, CA, USA) in duplicate. For all cases, assignment to the diagnostic group was performed centrally at Genoptix Medical Laboratory (Carlsbad, CA, USA).

Based on bone marrow findings, 17% of the enrollees were diagnosed with MDS, 15% with idiopathic cytopenias of undetermined significance (ICUS) and some evidence of dysplasia, and 69% with ICUS and no dysplasia. Bone marrow DNA was sequenced for mutations in 22 frequently mutated myeloid malignancy genes. Somatic mutations were identified in 71% of MDS patients, 62% of patients with ICUS and some dysplasia, and 20% of ICUS patients and no dysplasia. In total, 35% of ICUS patients carried a somatic mutation or chromosomal abnormality indicative of clonal hematopoiesis.

Rafael Bejar, MD, PhD, assistant professor of medicine and senior author of the study, said, “We don't know to what extent patients who have low blood counts and mutations are at increased risk of developing an overt malignancy. We hope that by defining CCUS, future studies will follow these patients to learn what these mutations mean for their future as their genetically abnormal cells may represent early stages of subsequent blood cancers.” The authors concluded that CCUS is a more frequent diagnosis than MDS in cytopenic patients. The study was published on October 1, 2015, in the journal Blood.

Related Links:

Moores Cancer Center
Fluidigm Corporation
Illumina 



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Enterovirus Test
Quanty Enterovirus System
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New automated lab procedures can detect opioids in tiny amounts of blood (Photo courtesy of Tripathi Lab/Brown University)

First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns

As the opioid crisis continues to impact communities across the United States, laboratories encounter significant difficulties in accurately detecting opioid substances in individuals with opioid use disorder.... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.